Will larotrectinib (Vitaika) affect the safety of other medications for patients with chronic diseases?

Larotrectinib is an oral targeted drug targeting NTRK fusion-positive tumors. It mainly exerts anti-tumor effects by inhibiting the TRK tyrosine kinase signaling pathway. For patients with chronic diseases, such as those with hypertension, diabetes or cardiovascular disease, who take many types of drugs for a long time, it is particularly important to evaluate the potential interactions and safety of larotrectinib with other drugs.

Clinical data show that larotrectinib is mainly metabolized by the liver's CYP3A enzyme, so there may be interactions with chronic disease drugs that use CYP3A inhibitors or inducers. For example, certain antihypertensive drugs, antiepileptic drugs, or statin lipid-lowering drugs, when combined with larotrectinib, may cause changes in blood drug concentrations, thereby affecting efficacy or increasing the risk of adverse reactions. Therefore, special attention needs to be paid to dose adjustment and blood drug monitoring when these drugs are used together.

In addition, larotrectinib may cause mild increases in liver function indicators or hematological changes. For patients with liver or kidney disease, liver and kidney function need to be monitored regularly to prevent drug additive toxicity. In addition, anticoagulants, hypoglycemic drugs or heart rhythm management drugs commonly used in patients with chronic diseases may also have increased adverse reactions when combined with larotrectinib, and doctors need to make adjustments based on the patient's specific medication conditions.

Overall, when larotrectinib is used in patients with chronic diseases, potential drug interactions and organ function status need to be comprehensively evaluated. Advise patients to provide a list of all long-term medications to their physician before starting larotrectinib treatment and to monitor regularly during treatment. Through scientific medication management and individualized adjustment, the efficacy can be maximized while reducing the safety risks of patients with chronic diseases while using larotrectinib.

Reference materials:https://www.drugs.com/